PATIENCE JOHN
Known title: DirectorCIK: 0001021413
PATIENCE JOHN's purchase track record
How the stock did after each of PATIENCE JOHN's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
6
of 6 since August 19, 2021
Stock higher 6 months later
0%
3 months: 17%
Median 6-month return
-60.8%
3 months: -22.3%
Beat the S&P 500
17%
median -50.0% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/5/2024 | BDSX | $104K | -25.4% | -66.6% | -3.0% |
| 11/21/2022 | BDSX | $2.00M | +76.9% | -13.9% | +6.1% |
| 4/7/2022 | BDSX | $500K | 0.0% | -16.2% | -16.8% |
| 12/30/2021 | BDSX | $700K | -61.7% | -62.8% | -20.8% |
| 11/18/2021 | BDSX | $122K | -48.9% | -75.1% | -17.1% |
| 8/19/2021 | BDSX | $67K | -19.1% | -58.7% | -0.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| BDSX | ▲ Buy | Option Exercise | 1,361 | — | 6/30/2026 | View on chart |
| BDSX | ▲ Buy | Option Exercise | 1,361 | — | 3/31/2026 | View on chart |
| BDSX | ▲ Buy | Option Exercise | 1,143 | — | 1/5/2026 | View on chart |
| BDSX | ▲ Buy | Option Exercise | 1,144 | — | 9/30/2025 | View on chart |
| BDSX | ▲ Buy | Option Exercise | 22,874 | — | 6/30/2025 | View on chart |
| BDSX | ▲ Buy | Option Exercise | 46,686 | — | 3/31/2025 | View on chart |
| BDSX | ▲ Buy | Open Market | 75,000 | $104K | 11/5/2024 | View on chart |
| BDSX | ▲ Buy | Option Exercise | 217,400 | — | 5/23/2024 | View on chart |
| BDSX | ▲ Buy | Grant | 61,728 | $100K | 8/3/2023 | View on chart |
| BDSX | ▲ Buy | Open Market | 1,739,130 | $2.0M | 11/21/2022 | View on chart |
| BDSX | ▲ Buy | Open Market | 279,329 | $500K | 4/7/2022 | View on chart |
| BDSX | ▲ Buy | Open Market | 137,931 | $600K | 12/30/2021 | View on chart |
| BDSX | ▲ Buy | Open Market | 22,988 | $100K | 12/30/2021 | View on chart |
| BDSX | ▲ Buy | Open Market | 10,000 | $62K | 11/23/2021 | View on chart |
| BDSX | ▲ Buy | Open Market | 9,497 | $60K | 11/18/2021 | View on chart |
| BDSX | ▲ Buy | Open Market | 8,396 | $67K | 8/19/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Biodesix Expands MRD Monitoring Through New Partnerships
Biodesix announced progress in two collaborative programs aimed at tumor‑informed and tumor‑naïve molecular residual disease (MRD) solutions. The company also advanced its MRD monitoring programs by partnering with Bio‑Rad and Thermo Fisher. These developments broaden Biodesix’s portfolio of diagnostic tools for cancer patients.
Biodesix Expands MRD Monitoring Through New Partnerships. Biodesix announced progress in two collaborative programs aimed at tumor‑informed and tumor‑naïve molecular residual disease (MRD) solutions. The company also advanced its MRD monitoring programs by partnering with Bio‑Rad and Thermo Fisher. These developments broaden Biodesix’s portfolio of diagnostic tools for cancer patients.